US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
ES2326964T3
(en)
*
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
GLICOPROTEIN COMPOSITIONS.
|
EP1463752A4
(en)
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
Albumin fusion proteins
|
EP2277889B1
(en)
|
2001-12-21 |
2014-07-09 |
Human Genome Sciences, Inc. |
Fusion proteins of albumin and interferon beta
|
US20070161087A1
(en)
*
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
BRPI0411132B8
(en)
*
|
2003-06-12 |
2021-05-25 |
Lilly Co Eli |
heterologous fusion protein and its uses
|
BRPI0507026A
(en)
|
2004-02-09 |
2007-04-17 |
Human Genome Sciences Inc |
albumin fusion proteins
|
US20090232807A1
(en)
*
|
2004-12-22 |
2009-09-17 |
Eli Lilly And Company |
Glp-1 analog fusion protein formulations
|
PT1881850E
(en)
*
|
2005-05-13 |
2010-11-26 |
Lilly Co Eli |
Glp-1 pegylated compounds
|
CN101273134B
(en)
*
|
2005-07-27 |
2012-01-04 |
王庆华 |
Glp/1/exendin 4 igg fc fusion constructs for treatment of diabetes and method
|
CA2658678A1
(en)
|
2005-08-06 |
2007-02-15 |
Gerald J. Prud'homme |
Composition and method for prevention and treatment of type i diabetes
|
ES2397289T3
(en)
*
|
2005-09-22 |
2013-03-06 |
Biocompatibles Uk Ltd. |
GLP-1 fusion polypeptides (glucagon-like peptide 1) with increased peptidase resistance
|
WO2007067828A2
(en)
*
|
2005-10-24 |
2007-06-14 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
ES2586236T3
(en)
|
2005-11-04 |
2016-10-13 |
Glaxosmithkline Llc |
Procedures for administering hypoglycemic agents
|
WO2007056362A2
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
EP2573111A1
(en)
|
2006-04-20 |
2013-03-27 |
Amgen Inc. |
GLP-1 compounds
|
JP5290177B2
(en)
*
|
2006-08-31 |
2013-09-18 |
セントカー・インコーポレーテツド |
GLP-2 mimetibodies, polypeptides, compositions, methods and uses
|
CA2663047A1
(en)
*
|
2006-09-06 |
2008-03-13 |
Phase Bioscience, Inc. |
Therapeutic elastin-like polypeptide (elp) fusion proteins
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
EP3231440A1
(en)
|
2006-12-22 |
2017-10-18 |
CSL Behring GmbH |
Modified coagulation factors with prolonged in vivo half-life
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
MX2009006564A
(en)
*
|
2007-01-05 |
2009-06-26 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers.
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
JP2008169195A
(en)
*
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
Insulinotopic peptide drug combo using carrier material
|
ES2753183T3
(en)
|
2007-02-12 |
2020-04-07 |
Csl Behring Gmbh |
Therapeutic application of Kazal-type serine protease inhibitors
|
KR20090119876A
(en)
|
2007-02-15 |
2009-11-20 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Glucagon/glp-1 receptor co-agonists
|
EP2139509A2
(en)
*
|
2007-03-15 |
2010-01-06 |
Biogen Idec MA, Inc. |
Treatment of autoimmune disorders
|
DK2172479T3
(en)
*
|
2007-06-19 |
2016-12-19 |
Glytech Inc |
GLP-1 peptide having the sugar chain attached thereto
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
EP2185178B1
(en)
|
2007-08-03 |
2017-08-23 |
Eli Lilly And Company |
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
|
US8563527B2
(en)
*
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
EP2031064A1
(en)
*
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Method for increasing protein titres
|
US8981047B2
(en)
|
2007-10-30 |
2015-03-17 |
Indiana University Research And Technology Corporation |
Glucagon antagonists
|
ES2558155T3
(en)
*
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compounds showing glucacon antagonist activity and GLP-1 agonist
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
CN101983066B
(en)
*
|
2008-01-30 |
2016-06-29 |
印第安那大学科技研究公司 |
Insulin prodrug based on ester
|
JOP20190083A1
(en)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
Fgf21 mutant fusion polypeptides and uses thereof
|
PA8830501A1
(en)
|
2008-06-17 |
2010-07-27 |
Univ Indiana Res & Tech Corp |
GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
|
SG192405A1
(en)
*
|
2008-06-17 |
2013-08-30 |
Univ Indiana Res & Tech Corp |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
WO2009155257A1
(en)
*
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
|
ES2531464T3
(en)
|
2008-06-24 |
2015-03-16 |
Csl Behring Gmbh |
Factor VIII, von Willebrand factor or its complexes with prolonged in vivo half-life
|
CA2953975C
(en)
|
2008-06-27 |
2019-11-26 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
EA032727B1
(en)
|
2008-10-10 |
2019-07-31 |
Амген Инк. |
Fgf21 mutant proteolysis-resistant polypeptide and use thereof
|
JP2012512903A
(en)
|
2008-12-19 |
2012-06-07 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
Amide glucagon superfamily peptide prodrug
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
US20120052069A1
(en)
|
2009-05-05 |
2012-03-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
HRP20240135T1
(en)
|
2009-05-05 |
2024-04-12 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
SG176858A1
(en)
|
2009-06-16 |
2012-02-28 |
Univ Indiana Res & Tech Corp |
Gip receptor-active glucagon compounds
|
WO2010148142A1
(en)
*
|
2009-06-17 |
2010-12-23 |
Amgen Inc. |
Chimeric fgf19 polypeptides and uses thereof
|
CN101993485B
(en)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
|
WO2011043530A1
(en)
*
|
2009-10-09 |
2011-04-14 |
(주)알테오젠 |
Glp-1 analog fusions, and composition for preventing or treating diabetes containing the fusions as an active ingredient
|
JP2013512672A
(en)
*
|
2009-12-02 |
2013-04-18 |
アムジエン・インコーポレーテツド |
Human FGFR1c, human β-croto-, and binding proteins that bind to both human FGFR1c and human β-croto-
|
UA109888C2
(en)
|
2009-12-07 |
2015-10-26 |
|
ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
EP2528618A4
(en)
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
EP2371857A1
(en)
|
2010-04-01 |
2011-10-05 |
CSL Behring GmbH |
Factor XII inhibitors for treating interstitial lung disease
|
AU2011239689A1
(en)
|
2010-04-15 |
2012-11-08 |
Amgen Inc. |
Human FGF receptor and beta-Klotho binding proteins
|
US20130123460A1
(en)
|
2010-04-30 |
2013-05-16 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
|
EP2569000B1
(en)
|
2010-05-13 |
2017-09-27 |
Indiana University Research and Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
CA2797089A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
|
CN101891823B
(en)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
Exendin-4 and analog fusion protein thereof
|
MX2012014576A
(en)
|
2010-06-24 |
2013-02-21 |
Univ Indiana Res & Tech Corp |
Amide based glucagon superfamily peptide prodrugs.
|
CN103415300B
(en)
*
|
2010-07-20 |
2018-02-23 |
诺沃—诺迪斯克有限公司 |
FGF21 compounds end modified N
|
MA34885B1
(en)
|
2010-12-22 |
2014-02-01 |
Indiana Unversity Res And Technology Corp |
GLUCAGON ANALOGS HAVING A GIP RECEPTOR ACTIVITY
|
RU2606016C2
(en)
|
2011-01-14 |
2017-01-10 |
Редвуд Байосайнс, Инк. |
Aldehyde marked immunoglobulin polypeptides and methods of their application
|
EP2497489A1
(en)
|
2011-03-09 |
2012-09-12 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
|
CA2829037C
(en)
|
2011-03-09 |
2022-05-17 |
Csl Behring Gmbh |
Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
|
PT2691417T
(en)
|
2011-03-29 |
2018-10-31 |
Roche Glycart Ag |
Antibody fc variants
|
US9156902B2
(en)
|
2011-06-22 |
2015-10-13 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
BR112013032717A2
(en)
|
2011-06-22 |
2017-01-24 |
Univ Indiana Res & Tech Corp |
glucagon / glp-1 receptor coagonists
|
JP6253578B2
(en)
|
2011-07-22 |
2017-12-27 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
Inhibitory anti-factor XII / XIIA monoclonal antibodies and their use
|
UY34317A
(en)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
T cell antireceptor antibody (alpha) / ß
|
KR20130049671A
(en)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
Method for preparation of biological active polypeptide conjugate
|
CA2847246A1
(en)
|
2011-11-17 |
2013-05-23 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
PL2814502T3
(en)
|
2012-02-15 |
2018-02-28 |
Csl Behring Gmbh |
Von willebrand factor variants having improved factor viii binding affinity
|
CA2877358A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
HUE056217T2
(en)
|
2012-07-13 |
2022-02-28 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
PT3366705T
(en)
*
|
2012-09-12 |
2023-07-19 |
Genzyme Corp |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
US9474803B2
(en)
|
2012-11-27 |
2016-10-25 |
Alteogen Inc. |
Composition for stabilizing fusion protein in which protein and FC domain are fused
|
HUE039334T2
(en)
|
2012-11-27 |
2018-12-28 |
Biomarin Pharm Inc |
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
|
CA2901225C
(en)
|
2013-03-08 |
2023-09-19 |
Csl Behring Gmbh |
Treatment and prevention of remote ischemia-reperfusion injury
|
IL275376B2
(en)
|
2013-03-11 |
2024-01-01 |
Genzyme Corp |
Hyperglycosylated binding polypeptides
|
US9580486B2
(en)
*
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
WO2014158900A1
(en)
|
2013-03-14 |
2014-10-02 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
EP2796145B1
(en)
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
|
US20160166660A1
(en)
|
2013-06-28 |
2016-06-16 |
Csl Behring Gmbh |
Combination therapy using a factor xii inhibitor and a c-1 inhibitor
|
CN103408669B
(en)
|
2013-08-01 |
2016-01-20 |
江苏泰康生物医药有限公司 |
GLP-1 analog fusion, and its production and use
|
CN104592381A
(en)
*
|
2013-10-31 |
2015-05-06 |
江苏万邦生化医药股份有限公司 |
Preparation method of liraglutide intermediate polypeptide
|
US20170065678A1
(en)
|
2014-03-11 |
2017-03-09 |
Novartis Ag |
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
|
SG10201808158UA
(en)
|
2014-03-19 |
2018-10-30 |
Genzyme Corp |
Site-specific glycoengineering of targeting moieties
|
EP3889185A3
(en)
*
|
2014-03-31 |
2022-01-26 |
Hanmi Pharm. Co., Ltd. |
Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
|
AU2015276089B2
(en)
|
2014-06-18 |
2021-03-18 |
Csl Behring Gmbh |
Therapy using a Factor XII inhibitor in a neurotraumatic disorder
|
CN106659771B
(en)
|
2014-07-02 |
2021-09-24 |
康诺贝林伦瑙有限公司 |
Modified von Willebrand factor
|
MX2017000821A
(en)
|
2014-07-21 |
2017-08-18 |
Delinia Inc |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases.
|
HUE043038T2
(en)
|
2014-08-11 |
2019-07-29 |
Delinia Inc |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
CN108271356A
(en)
|
2014-09-24 |
2018-07-10 |
印第安纳大学研究及科技有限公司 |
Duodenin-insulin conjugate
|
CN104293834B
(en)
*
|
2014-10-11 |
2018-03-23 |
上海兴迪金生物技术有限公司 |
GLP 1 or its analog and antibody Fc fragment fusion protein preparation method
|
RS59154B1
(en)
|
2014-12-23 |
2019-10-31 |
Novo Nordisk As |
Fgf21 derivatives and uses thereof
|
KR101825048B1
(en)
*
|
2014-12-31 |
2018-02-05 |
주식회사 제넥신 |
Fusion Polypeptide Comprising GLP and Immunoglobulin Hybrid Fc and use thereof
|
MX2017012966A
(en)
|
2015-04-10 |
2018-06-06 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells.
|
AR105616A1
(en)
*
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
FUSION PROTEINS
|
EP4089109A3
(en)
|
2015-05-22 |
2023-03-01 |
CSL Behring Lengnau AG |
Methods for preparing modified von willebrand factor
|
ES2774011T3
(en)
|
2015-05-22 |
2020-07-16 |
CSL Behring Lengnau AG |
Truncated von Willebrand factor polypeptides to treat hemophilia
|
TWI622596B
(en)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
Glucagon receptor agonists
|
KR20170049319A
(en)
|
2015-10-28 |
2017-05-10 |
주식회사유한양행 |
Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
|
KR20170049320A
(en)
|
2015-10-28 |
2017-05-10 |
주식회사유한양행 |
Dual function proteins and pharmaceutical composition comprising the same
|
EP3184149A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Soluble glycoprotein v for treating thrombotic diseases
|
PE20181327A1
(en)
|
2015-12-23 |
2018-08-20 |
Amgen Inc |
METHOD TO TREAT OR IMPROVE METABOLIC DISORDERS WITH GASTRIC INHIBITOR PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
|
SG11201805494WA
(en)
|
2016-01-07 |
2018-07-30 |
Csl Behring Recombinant Facility Ag |
Mutated von willebrand factor
|
BR112018013861A2
(en)
|
2016-01-07 |
2018-12-18 |
Csl Behring Recombinant Facility Ag |
polypeptide, complex, pharmaceutical composition, methods for treating a blood clotting disorder, for producing a polypeptide and dimer of a polypeptide, for increasing factor viii half life and for increasing dimerization of said polypeptide, use of a polypeptide, kit pharmaceutical, plasmid or vector, and host cell
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
JP7456723B2
(en)
|
2016-04-06 |
2024-03-27 |
シーエスエル、リミテッド |
How to treat atherosclerosis
|
CA3019398A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
US10336812B2
(en)
*
|
2016-05-10 |
2019-07-02 |
Janssen Biotech, Inc. |
GDF15 fusion proteins and uses thereof
|
EP3502143A4
(en)
|
2016-08-19 |
2020-07-15 |
Ampsource Biopharma Shanghai Inc. |
Linker peptide for constructing fusion protein
|
CN106279437B
(en)
|
2016-08-19 |
2017-10-31 |
安源医药科技(上海)有限公司 |
Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
|
CN107759694B
(en)
|
2016-08-19 |
2023-01-13 |
安源医药科技(上海)有限公司 |
Bispecific antibody, preparation method and application thereof
|
EA201991142A1
(en)
|
2016-11-08 |
2019-10-31 |
|
OPTIONS IL-2 FOR TREATMENT OF AUTOIMMUNE DISEASES
|
JP7328891B2
(en)
|
2016-11-10 |
2023-08-17 |
ユーハン・コーポレイション |
Pharmaceutical compositions for preventing or treating hepatitis, liver fibrosis, and cirrhosis containing fusion proteins
|
DK3538134T3
(en)
|
2016-11-11 |
2022-02-07 |
CSL Behring Lengnau AG |
TRUNKED VON WILLEBRAND FACTOR POLYPEPTIDES FOR EXTRAVASCULAR ADMINISTRATION FOR THE TREATMENT OR PROPHYLAXATION OF A BLOOD COAGULATION DISORDER
|
AU2017358861B2
(en)
|
2016-11-11 |
2022-02-17 |
CSL Behring Lengnau AG |
Truncated von Willebrand Factor polypeptides for treating hemophilia
|
EP3351262A1
(en)
|
2016-12-30 |
2018-07-25 |
Istanbul Universitesi Rektorlugu |
Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
|
JOP20190177A1
(en)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
|
EA201992516A1
(en)
|
2017-04-21 |
2020-04-09 |
Юхан Корпорейшн |
METHOD FOR PRODUCING BIFUNCTIONAL PROTEINS AND THEIR DERIVATIVES
|
SI3630164T1
(en)
|
2017-06-01 |
2023-10-30 |
Eli Lilly And Company |
Dulaglutide for the treatment of chronic kidney disease
|
ES2966835T3
(en)
|
2017-06-22 |
2024-04-24 |
CSL Behring Lengnau AG |
Modulation of FVIII immunogenicity by truncated VWF
|
WO2019060653A1
(en)
|
2017-09-22 |
2019-03-28 |
Regeneron Pharmaceuticals, Inc. |
Glucagon-like peptide 1 receptor agonists and uses thereof
|
JOP20200126A1
(en)
|
2017-11-21 |
2020-05-21 |
Lilly Co Eli |
Methods of using and compositions containing dulaglutide
|
US11752173B2
(en)
|
2017-12-19 |
2023-09-12 |
Beijing Jiyuan Biological Technology Co., Ltd. |
FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
|
WO2019125003A1
(en)
*
|
2017-12-22 |
2019-06-27 |
케이비바이오메드 주식회사 |
Oral gene carrier and use thereof
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
US11679143B2
(en)
|
2018-02-08 |
2023-06-20 |
Sunshine Lake Pharma Co., Ltd. |
FGF21 variant, fusion protein and application thereof
|
KR20200135618A
(en)
|
2019-05-23 |
2020-12-03 |
㈜ 디앤디파마텍 |
Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease comprising a polypeptide
|
BR112021000933A2
(en)
|
2018-07-19 |
2021-04-27 |
D&D Pharmatech Inc. |
polypeptide, pharmaceutical composition, method of preparing it and method of preventing or treating diseases
|
CN110878127B
(en)
|
2018-09-06 |
2022-06-28 |
浙江柏拉阿图医药科技有限公司 |
Long-acting recombinant GLP1-Fc-CD47 protein and preparation and application thereof
|
CN111234000B
(en)
*
|
2018-11-28 |
2023-05-26 |
鲁南制药集团股份有限公司 |
Ai Saina peptide analogues
|
CN111269312B
(en)
*
|
2018-12-04 |
2023-05-09 |
鲁南制药集团股份有限公司 |
Heterologous fusion protein
|
CN109836486B
(en)
*
|
2019-01-30 |
2020-09-08 |
北京双因生物科技有限公司 |
Fibroblast growth factor 21 variants, fusion proteins thereof, and uses thereof
|
CN111662373A
(en)
*
|
2019-03-05 |
2020-09-15 |
广东东阳光药业有限公司 |
Polypeptide molecule and application thereof
|
EP3934679A1
(en)
|
2019-03-08 |
2022-01-12 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
CA3128522C
(en)
|
2019-03-15 |
2024-04-02 |
Eli Lilly And Company |
Preserved formulations
|
CA3177693A1
(en)
|
2019-04-05 |
2020-10-05 |
Eli Lilly And Company |
Therapeutic uses of dulaglutide
|
US20220211808A1
(en)
|
2019-05-17 |
2022-07-07 |
Universitaet Zuerich |
Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
|
KR20220029733A
(en)
|
2019-07-04 |
2022-03-08 |
체에스엘 베링 렝나우 아게 |
truncated von Willebrand factor (VWF) to increase the in vitro stability of coagulation factor VIII
|
EP4045641A1
(en)
|
2019-10-15 |
2022-08-24 |
Eli Lilly and Company |
Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
|
WO2021094344A1
(en)
|
2019-11-11 |
2021-05-20 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
CN115322794A
(en)
|
2020-01-11 |
2022-11-11 |
北京质肽生物医药科技有限公司 |
Conjugates of fusion proteins of GLP-1 and FGF21
|
US20230372539A1
(en)
|
2020-08-24 |
2023-11-23 |
The Trustees Of The University Of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
CN114106194B
(en)
*
|
2020-08-31 |
2024-01-16 |
中国科学院天津工业生物技术研究所 |
Fusion protein for treating diabetes and/or obesity
|
JP2023551193A
(en)
|
2020-11-20 |
2023-12-07 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
Methods for treating antibody-related rejection
|
CN114685644A
(en)
|
2020-12-29 |
2022-07-01 |
苏州康宁杰瑞生物科技有限公司 |
Human GLP-1 polypeptide variant and application thereof
|
KR20230142569A
(en)
|
2021-02-01 |
2023-10-11 |
체에스엘 베링 아게 |
Methods for Treating or Preventing Secondary Neurological Adverse Events After Hemorrhagic Stroke
|
WO2022234070A1
(en)
|
2021-05-07 |
2022-11-10 |
Csl Behring Ag |
Expression system for producing a recombinant haptoglobin (hp) beta chain
|
CN117616037A
(en)
|
2021-07-06 |
2024-02-27 |
苏州康宁杰瑞生物科技有限公司 |
Fusion proteins and uses thereof
|
WO2023225534A1
(en)
|
2022-05-18 |
2023-11-23 |
Protomer Technologies Inc. |
Aromatic boron-containing compounds and related insulin analogs
|
CN114774496B
(en)
*
|
2022-06-21 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
Method for preparing GLP-1 analogue through high-density fermentation
|
WO2024047219A1
(en)
|
2022-09-02 |
2024-03-07 |
Csl Behring Ag |
Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
|
WO2024064842A1
(en)
|
2022-09-21 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating obesity, diabetes, and liver dysfunction
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|